Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23685544.
- Also identified by DOI 10.1016/j.bone.2013.04.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Bone Density Conservation Agents
- Bone Neoplasms
- Hypocalcemia
- Prostatic Neoplasms